BRAF and neoplasm: AZD6244 had significant efficacy in BRAF PTEN mice, although in BRAF P53, despite short-term suppression of tumor growth, rapid regrowth suggested either intrinsic resistance, or the ability to rapidly reactivate suppressed signaling pathways (Fig. 2A and B).